Viiv Healthcare

This study tested a once-daily pill containing two HIV drugs (dolutegravir and lamivudine) in 32 teens aged 12 to 18 who had never taken HIV medication before. The goal was to see if this simpler two-drug regimen could safely control the virus after 48 weeks. Results showed the p…

This study gave children and teens with HIV continued access to the drug dolutegravir after they finished earlier clinical trials. About 100 participants who were already doing well on the medication received it every 12 weeks until local approved versions became available. The g…

This study looked at whether adults aged 50 and older with HIV could safely switch from a three-drug pill to a two-drug pill (DTG/3TC) while keeping the virus under control. About 200 participants who already had undetectable virus levels made the switch. The main goal was to see…

This study tested a new experimental drug called VH4524184 for HIV in 84 healthy adults. The main goal was to see if the drug is safe and how the body processes it. Researchers also looked at whether the drug affects certain liver enzymes. This is an early-stage trial, so it does…

This study tested two experimental oral medications (VH4004280 and VH4011499) in 44 adults with HIV who had never taken HIV drugs before. The goal was to see how well these drugs lower the amount of virus in the blood over 10 days. The study also checked for side effects. These d…

This study looked at two different strategies for giving cabotegravir, a long-acting HIV prevention shot, to HIV-negative men who have sex with men and transgender men in U.S. clinics. About 287 participants received the shot either after a month of pills or directly as injection…

This study looked at how to best give HIV prevention shots (called CAB PrEP) to Black cis and transgender women in the US. Researchers tested different ways to offer the shots in clinics and asked both patients and staff what worked well and what didn't. The goal was to make it e…

This completed Phase 1 study looked at how the experimental HIV drug VH4524184 is absorbed by the body and how it interacts with food and other common medicines. It involved 126 healthy adults aged 18 to 60. The goal was to gather important information for future use, not to trea…

This early-stage study tested two different versions of a long-acting HIV drug called cabotegravir in 56 healthy adults. The goal was to see how safe the drugs are and how they behave in the body over time. Participants received a single injection and were monitored for side effe…